<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04039204</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00059474</org_study_id>
    <nct_id>NCT04039204</nct_id>
  </id_info>
  <brief_title>Elagolix for Fertility Enhancement Clinical Trial</brief_title>
  <acronym>EFFECT</acronym>
  <official_title>Elagolix for Fertility Enhancement Clinical Trial (EFFECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies suggest that undiagnosed endometriosis results in poor reproductive outcomes in the
      setting of In Vitro Fertilization and Embryo Transfer (IVF-ET). Biomarkers that predict
      endometriosis including B-cell lymphoma (BCL6) and Sirtuin 1 (SIRT1) are associated with
      reduced pregnancy rates following IVF-ET. Treatment with gonadotropin releasing hormone
      (GnRHr) receptor agonists (leuprolide acetate depot) has been shown to improve pregnancy
      rates following embryo transfer (ET). In this randomized controlled trial, a new generation
      GnRHr antagonist, elagolix, will be compared to oral contraceptives (OCPs) for suppression of
      suspected endometriosis prior to ET. Both groups will receive two months of treatment prior
      to frozen embryo transfer of a single euploid embryo. Non-treatment controls will also be
      included. Outcomes will include pregnancy rate, miscarriage rate and ongoing and live birth
      rate following treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although meta-analyses have not demonstrated an effect of endometriosis on IVF outcomes, most
      women with endometriosis undergoing IVF have not been diagnosed or treated for their disease.
      Recent evidence suggests that biomarkers for endometriosis predict IVF failure and
      miscarriage. Further suppression of endometriosis prior to IVF has been shown to dramatically
      improve pregnancy rates in unexplained infertility with suspected endometriosis. Elagolix
      (Orilissa) is a new generation FDA approved orally active GnRHr antagonist that is rapidly
      reversible, for the treatment of endometriosis and pelvic pain. There have been no studies on
      the efficacy of elagolix for the treatment of endometriosis-associated infertility. Given the
      recent study in Fertility and Sterility demonstrating IVF outcome prediction using BCL6 as a
      biomarker for the presence of endometriosis and subsequent preliminary data showing benefit
      using surgery and GnRH agonist therapy, there is adequate rationale to examine the use of the
      orally active, non-peptide compound (elagolix) for estrogen suppression prior to frozen
      embryo transfer in women who test positive for BCL6 and an associated protein, SIRT1. In this
      multi-central randomized controlled trial (RCT), the EFFECT Trial, the investigators plan to
      recruit 100 subjects with prior unexplained IVF failure with positive endometrial BCL6/SIRT1
      expression. To qualify all subjects will need to have a preimplantation genetic testing
      (PGT-A) tested euploid embryo and intentions to undergo frozen embryo transfer. Subjects will
      be randomized to receive elagolix (200 mg BID) or OCPs for 2 months prior to standardized
      FET. Primary study outcomes will be pregnancy outcome.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Subjects in the OCP group who fail FET but have remaining euploid embryos will be offered 2 additional months of elagolix followed by another FET</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 to 15 weeks</time_frame>
    <description>The number of viable pregnancies divided by number of frozen embryo transfers</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>9 months</time_frame>
    <description>The number of live births divided by number of transfers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Miscarriage rate</measure>
    <time_frame>15 week</time_frame>
    <description>The number of subjects with a first trimester pregnancy loss divided by the number of pregnancies</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Endometriosis</condition>
  <condition>Unexplained Infertility</condition>
  <arm_group>
    <arm_group_label>Elagolix</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elagolix will be dosed at the higher dose used in pelvic pain trials, 200 mg twice a day for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral contraceptives (Ortho Cyclen)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Elagolix will be compared to a less potent standard commonly used prior to IVF or embryo transfer, namely estrogen containing birth control pills.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will be followed without treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elagolix</intervention_name>
    <description>This orally active, reversible GnRH antagonist will be used to suppress endometriosis by lowering estrogen levels for 2 months prior to FET</description>
    <arm_group_label>Elagolix</arm_group_label>
    <arm_group_label>Oral contraceptives (Ortho Cyclen)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Anti-Mullerian Hormone (AMH) &gt; 0.5 and &lt; 5

          -  At least 1 euploid embryo for transfer

          -  Prior endometrial biopsy showing elevated BCL6 and SIRT1 expression

          -  Endometrial thickness &gt; 5.9 and &lt; 14 mm

        Exclusion Criteria:

          -  Uterine fibroids &gt; 4 cm (intramural)

          -  Polycystic ovary syndrome (Rotterdam criteria)

          -  Ovarian failure and donor eggs or oocytes

          -  Positive lupus anticoagulant or positive anti-cardiolipin antibody testing

          -  Diabetes mellitus (Type I or II)

          -  Untreated hypothyroidism

          -  Untreated hyperprolactinemia

          -  BMI &lt;17 or &gt; 35

          -  Uncorrected uterine anomaly
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only women with infertility seeking embryo transfer are eligible to participate</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce A Lessey, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bruce A Lessey, MD, PhD</last_name>
    <phone>336-716-6476</phone>
    <email>blessey@wakehealth.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dan Angress</last_name>
    <phone>310-227-6607</phone>
    <email>dan@cicerodx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wake Forest Univesity Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Taylor HS, Giudice LC, Lessey BA, Abrao MS, Kotarski J, Archer DF, Diamond MP, Surrey E, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Rowan JP, Duan WR, Ng J, Schwefel B, Thomas JW, Jain RI, Chwalisz K. Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist. N Engl J Med. 2017 Jul 6;377(1):28-40. doi: 10.1056/NEJMoa1700089. Epub 2017 May 19.</citation>
    <PMID>28525302</PMID>
  </reference>
  <reference>
    <citation>Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer DF, Diamond MP, Johnson NP, Watts NB, Gallagher JC, Simon JA, Carr BR, Dmowski WP, Leyland N, Singh SS, Rechberger T, Agarwal SK, Duan WR, Schwefel B, Thomas JW, Peloso PM, Ng J, Soliman AM, Chwalisz K. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies. Obstet Gynecol. 2018 Jul;132(1):147-160. doi: 10.1097/AOG.0000000000002675. Erratum in: Obstet Gynecol. 2018 Dec;132(6):1507-1508.</citation>
    <PMID>29889764</PMID>
  </reference>
  <reference>
    <citation>Likes CE, Cooper LJ, Efird J, Forstein DA, Miller PB, Savaris R, Lessey BA. Medical or surgical treatment before embryo transfer improves outcomes in women with abnormal endometrial BCL6 expression. J Assist Reprod Genet. 2019 Mar;36(3):483-490. doi: 10.1007/s10815-018-1388-x. Epub 2019 Jan 4.</citation>
    <PMID>30610661</PMID>
  </reference>
  <reference>
    <citation>Almquist LD, Likes CE, Stone B, Brown KR, Savaris R, Forstein DA, Miller PB, Lessey BA. Endometrial BCL6 testing for the prediction of in vitro fertilization outcomes: a cohort study. Fertil Steril. 2017 Dec;108(6):1063-1069. doi: 10.1016/j.fertnstert.2017.09.017. Epub 2017 Nov 7.</citation>
    <PMID>29126613</PMID>
  </reference>
  <reference>
    <citation>Littman E, Giudice L, Lathi R, Berker B, Milki A, Nezhat C. Role of laparoscopic treatment of endometriosis in patients with failed in vitro fertilization cycles. Fertil Steril. 2005 Dec;84(6):1574-8.</citation>
    <PMID>16359945</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>June 26, 2020</last_update_submitted>
  <last_update_submitted_qc>June 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Endometriosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

